Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema

Completed

• Conditions: Diabetic Macular Edema

• Registration Number: NCT00563940
• Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Brief Summary

Diabetic macular edema is a common complication of ocular diabetes mellitus and can cause blindness. Hypoxygenation of the retina stimulates tissue mediators, especially different subtypes of vascular endothelial growth factor (VEGF). VEGF is responsible for proliferation, extension and increased permeability of the vessels. The aim of our study was to examine the short-term effect of intravitreal bevacizumab (Avastin® 1.25 mg in 0.05 ml) and triamcinolone on visual acuity and central retinal thickness in patients with clinically significant diabetic macular edema (CSME).

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2007-11-26
• Study First Submitted QC: 2007-11-26
• Study First Posted: 2007-11-27
• Primary Completion: 2010-02
• Study Completion: 2010-02
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-04
• Last Update Posted: 2019-07-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• clinical significant macular edema

Exclusion Criteria

• retinal thickness < 250 µm

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Central retinal thickness	4, 8, 12, 24, 72, and 168 hours

Secondary Outcome Measures

Name	Time	Method
BCVA	4, 8, 12, 24, 72, and 168 hours

Trial Locations

Locations (1)

Klinik und Poliklinik für Augenheilkunde; 🇨🇭 Bern, Switzerland